尽管价格目标降低,但Regeneron的库存猛增至700.64美元,保持了76.99B的市场上限。 Despite lowered price targets, Regeneron's stock surged to $700.64, maintaining a $76.99B market cap.

几位分析家最近降低了Regenenron制药公司(ReGN)的价格目标,包括TD Cowen、BMO资本市场和Leerink Partners,尽管评分仍为正数。 Several analysts have recently lowered their price targets for Regeneron Pharmaceuticals (REGN), including TD Cowen, BMO Capital Markets, and Leerink Partners, though ratings remain positive. 尽管价格目标有所降低,Regeneron的库存却增加到700.64美元。 Despite the price target reductions, Regeneron's stock saw an increase to $700.64. 该公司以发展治疗肌肉畸形等疾病而著称,其市场上限为769.9亿美元,主要由机构投资者拥有。 The company, known for developing treatments for diseases like macular degeneration, has a market cap of $76.99 billion and is primarily owned by institutional investors.